Chemical formula: C₂₈H₂₇NO₄S Molecular mass: 473.583 g/mol PubChem compound: 5035
Raloxifene is indicated for:
Population group: women, only adults (18 years old or older)
Raloxifene is indicated for the treatment of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.
When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: women, only adults (18 years old or older)
Raloxifene is indicated for the prevention of osteoporosis in postmenopausal women.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Raloxifene is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
